bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a report on Friday, November 15th. Robert W. Baird dropped their price objective on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, August 15th. Wells Fargo & Company reduced their target price on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Finally, JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.03.

bluebird bio Stock Up 3.3 %

NASDAQ BLUE opened at $0.36 on Tuesday. The business has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The company has a market cap of $70.33 million, a P/E ratio of -0.19 and a beta of 0.76. bluebird bio has a one year low of $0.29 and a one year high of $5.53.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. Research analysts anticipate that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the period. Geode Capital Management LLC lifted its stake in bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares in the last quarter. State Street Corp boosted its position in shares of bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after buying an additional 43,382 shares during the period. Verition Fund Management LLC purchased a new position in shares of bluebird bio during the third quarter worth $42,000. Finally, Captrust Financial Advisors grew its stake in shares of bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares in the last quarter. 87.43% of the stock is owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.